- Home
- PRFX vs XXII Comparison
PRFX vs XXII Comparison
Compare PRFX & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRFX | XXII |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 3.3M |
| IPO Year | 2020 | 2011 |
Fundamental Metrics
Financial Performance| Metric | PRFX | XXII |
|---|---|---|
| Price | $2.81 | $4.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 227.6K | 29.5K |
| Earning Date | 01-01-0001 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,832,530.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $79.56 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.58 | $0.67 |
| 52 Week High | $3.71 | $11.37 |
Technical Indicators
Market Signals| Indicator | PRFX | XXII |
|---|---|---|
| Relative Strength Index (RSI) | 58.23 | 42.91 |
| Support Level | $1.28 | $1.68 |
| Resistance Level | $3.65 | $6.86 |
| Average True Range (ATR) | 0.41 | 0.66 |
| MACD | -0.08 | -0.35 |
| Stochastic Oscillator | 19.27 | 11.40 |
Price Performance
Historical ComparisonAbout PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.